Currently, vascular closure devices (VCDs) have been available in the US for diagnostic and interventional procedures since 1995. Since then, numerous devices have been introduced, and the VCD market has experienced substantial growth. VCDs aim to address the issues of manual compression, including time and bleeding complications. These devices can be categorized into two distinct methods of closure: active and passive closure. Active closure mechanically secures the arteriotomy, while passive closure relies on the delivery of material through the tissue tract.
Currently Approved VCDs
The following Table 1 lists the currently FDA-approved and marketed VCDs.
Table 1.
Several VCDs have been approved by the FDA, including Angio-Seal Evolution, Prostar XL, and StarClose SE. These devices have shown promising results in reducing bleeding and vascular complications compared to manual compression. Additionally, studies have demonstrated shorter times to hemostasis and ambulation with VCDs.
Future Outlook
The future growth of the VCD market is driven by the Centers for Medicare & Medicaid Services’ objective for an increase in outpatient percutaneous coronary intervention procedures, which will necessitate safe and early ambulation. The desire to avoid arterial cut-down procedures and the growth of large-device procedures also contribute to the market growth.
Conclusion
In conclusion, VCDs have shown promising results in improving patient comfort and reducing bleeding and vascular complications. As the market continues to grow, it is essential to address the challenges associated with VCD usage, including technical expertise required for deployment and potential complications. Further studies are needed to compare the performance of different VCDs and to determine the optimal device for specific applications.
Manual:
Chat: Powered By VoiceSphere